These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 19391290)

  • 21. Ibandronic acid: new drug. Osteoporosis: one tablet a month, but risk of a 'flu-like' syndrome.
    Prescrire Int; 2008 Feb; 17(93):11. PubMed ID: 18354857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. More on reports of esophageal cancer with oral bisphosphonate use.
    Solomon DH; Patrick A; Brookhart MA
    N Engl J Med; 2009 Apr; 360(17):1789-90; author reply 1791-2. PubMed ID: 19391255
    [No Abstract]   [Full Text] [Related]  

  • 23. Bisphosphonate therapy and dental treatment.
    Phillips G
    J Mich Dent Assoc; 2009 Aug; 91(8):40, 42-5. PubMed ID: 19722373
    [No Abstract]   [Full Text] [Related]  

  • 24. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
    Makras P; Hamdy NA; Zwinderman AH; Ballieux BE; Papapoulos SE
    Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Oral bisphosphonates and musculoskeletal disorders].
    González-Ruiz M; Encarnación González-Ruiz M; Villota Hoyos R; Rodríguez Muriedas P
    Aten Primaria; 2006; 38(3):184-5. PubMed ID: 16945282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Current use of bisphosphonates in clinical oncology].
    Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
    Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bisphosphonates: atypical fractures?
    Prescrire Int; 2009 Feb; 18(99):25. PubMed ID: 19396935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bisphosphonate medications--the good, the bad, and the ugly.
    Bourgeois SL
    Tex Dent J; 2009 Jul; 126(7):596-604. PubMed ID: 19753815
    [No Abstract]   [Full Text] [Related]  

  • 29. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series.
    Armamento-Villareal R; Napoli N; Diemer K; Watkins M; Civitelli R; Teitelbaum S; Novack D
    Calcif Tissue Int; 2009 Jul; 85(1):37-44. PubMed ID: 19548019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic kidney disease and bisphosphonate treatment: are prescribing guidelines unnecessarily restrictive?
    Courtney AE; Maxwell AP
    Postgrad Med J; 2009 Jun; 85(1004):327-30. PubMed ID: 19528309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
    Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
    J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review of comparative effectiveness of treatments to prevent fractures.
    Lim LS
    Ann Intern Med; 2008 Jun; 148(11):884-5; author reply 887. PubMed ID: 18519938
    [No Abstract]   [Full Text] [Related]  

  • 33. Determining the pharmacologic window of bisphosphonates that mitigates severe injury-induced osteoporosis and muscle calcification, while preserving fracture repair.
    Saito M; Moore-Lotridge SN; Uppuganti S; Egawa S; Yoshii T; Robinette JP; Posey SL; Gibson BHY; Cole HA; Hawley GD; Guelcher SA; Tanner SB; McCarthy JR; Nyman JS; Schoenecker JG
    Osteoporos Int; 2022 Apr; 33(4):807-820. PubMed ID: 34719727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment with bisphosphonates and previous dental health].
    Madrid C; Bouferrache K; Jaques B; Broome M
    Rev Med Suisse; 2009 Apr; 5(200):909-10; author reply 910-1. PubMed ID: 19438092
    [No Abstract]   [Full Text] [Related]  

  • 36. Case report of implant placement in a patient with Paget's disease on bisphosphonate therapy.
    Pirih FQ; Zablotsky M; Cordell K; McCauley LK
    J Mich Dent Assoc; 2009 May; 91(5):38-43. PubMed ID: 19537656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neridronic acid for the treatment of bone metabolic diseases.
    Gatti D; Viapiana O; Idolazzi L; Fracassi E; Adami S
    Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1305-11. PubMed ID: 19761412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bisphosphonates and dental implants: current problems.
    Flichy-Fernández AJ; Balaguer-Martínez J; Peñarrocha-Diago M; Bagán JV
    Med Oral Patol Oral Cir Bucal; 2009 Jul; 14(7):E355-60. PubMed ID: 19561566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies.
    Jansen JP; Bergman GJ; Huels J; Olson M
    Curr Med Res Opin; 2009 Aug; 25(8):1861-8. PubMed ID: 19530978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N; Campbell SC; Moritz T; Broderick WR; Iyer P; Arcenas AG; Van Veldhuizen PJ; Friedman N; Reda D; Warren S; Garewal H
    J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.